Inferior Vena Cava Filter

Related Subjects: |Pulmonary Embolism 🫁 |Assessing Breathlessness |Deep Vein Thrombosis |DVT/PE in pregnancy |CTPA In PE |Inferior Vena Cava Filter

IVC filters are mechanical devices placed in the inferior vena cava to trap thrombi from the lower extremities before they reach the pulmonary arteries. ⚠️ Their use should be specialist-led and individualised, as inappropriate placement carries significant long-term risks. Anticoagulation remains the first-line therapy for venous thromboembolism (VTE).

🧾 About

• A small metallic cage-like device deployed percutaneously into the infrarenal IVC.
• Designed to trap emboli arising from DVT, reducing risk of pulmonary embolism (PE).
• Modern practice favours retrievable filters.
• IVC filters do not dissolve clot and have no effect on the underlying hypercoagulable state.

🔍 Accepted Indications (Guideline-Supported)

• Absolute contraindication to anticoagulation (e.g. active major bleeding, recent intracranial haemorrhage, urgent neurosurgery).
• Recurrent PE despite confirmed therapeutic anticoagulation after optimisation (check adherence, dosing, drug interactions, and anticoagulant choice).
• Complication of anticoagulation requiring cessation (e.g. severe bleeding).
• Rarely, selected very high-risk trauma patients where anticoagulation is absolutely contraindicated and not feasible.

❌ Not Recommended / Controversial Uses

• Routine prophylaxis in surgical patients without VTE → not recommended.
• Routine adjunct to anticoagulation in PE → no mortality benefit.
• “Just in case” long-term placement → associated with harm.
• Stable patients who can receive anticoagulation → filter not indicated.

⚙️ Types of Filters

• Permanent filters – rarely used in modern UK practice.
• Retrievable filters – preferred; intended for removal once anticoagulation can be safely resumed.

📊 Evidence & Guidelines

• PREPIC Trial (1998; 2005 follow-up):
  • Reduced early PE incidence.
  • No mortality benefit.
  • Increased long-term DVT risk.
• Cochrane Review (2022): No survival advantage; increased DVT rates.
• NICE NG158 (updated 2023): Anticoagulation first-line. Consider IVC filter only if anticoagulation contraindicated or ineffective.
• ESC 2019 PE Guidelines: Restrict use to highly selected patients; recommend early retrieval when no longer required.
• ASH 2021 Guidelines: Recommend against routine filter use in addition to anticoagulation.

⚠️ Complications

• Early: Malposition, bleeding, access site complications, vessel injury.
• Intermediate: Filter thrombosis, migration.
• Late: Caval thrombosis, device fracture, penetration into adjacent structures (duodenum, aorta, vertebrae).
• Long-term DVT risk increased, particularly if filter not retrieved.

🔄 Retrieval & Governance

• Retrieval plan should be documented at time of insertion.
• Remove as soon as anticoagulation can be safely resumed.
• Retrieval success highest within weeks to a few months.
• Hospitals should operate a tracking system or registry to prevent loss to follow-up.
• Failure to retrieve is common and contributes to avoidable long-term harm.

📌 Clinical Pearls

• Always ask: “Why not anticoagulation?”
• Optimise anticoagulation before declaring treatment failure.
• Use filters as a temporary rescue strategy, not a substitute.
• Involve haematology and interventional radiology before placement.
• Document clear indication and retrieval plan.

📚 References

• PREPIC Study Group. Eight-Year Follow-Up of Patients With Permanent IVC Filters. NEJM 2005;352:146–53.
• NICE NG158 (Updated 2023)
• ESC Guidelines for the Diagnosis and Management of Acute PE (2019).
• ASH 2021 Guidelines for Management of Venous Thromboembolism.
• Cochrane Database Syst Rev. 2022; Vena caval filters for preventing PE.